Black Diamond Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Black Diamond Therapeutics generated cash of -$66,717,000, which is more than the previous year. Cash used in financing activities reached the amount of $71,932,000 last year. Net change in cash is therefore $21,561,000.
Cash Flow
| 2017 | -2.35M | -77K | 9.97M |
|---|---|---|---|
| 2018 | -8.45M | -76K | 52.31M |
| 2019 | -24.67M | -21K | 127.75M |
| 2020 | -52.14M | -281.69M | 214.94M |
| 2021 | -100.14M | 130.61M | 729K |
| 2022 | -85.08M | 53.36M | 177K |
| 2023 | -66.71M | 16.34M | 71.93M |
BDTX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 35.48M | 67.02M | 35.82M | 154.72M | 51.66M | 7.87M | 332K |
Operating activities | |||||||
Net income | -82.44M | -91.16M | -125.59M | -67.25M | -35.25M | -8.93M | -4.60M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 437K | 508K | 205K | 52K | 47K | 44K | 24K |
Stock-based compensation expense | 9.60M | 12.19M | 14.03M | 7.76M | 3.64M | 0 | 5K |
| Deferred income tax benefit | 9.60M | 12.19M | 14.03M | 7.76M | 3.64M | 0 | 5K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 597K | -2.23M | 1.56M | 1.06M | 1.45M | 264K | -59K |
Cash generated by operating activities | -66.71M | -85.08M | -100.14M | -52.14M | -24.67M | -8.45M | -2.35M |
Investing activities | |||||||
Purchases Of Investments | -61.88M | -60.14M | -49.50M | -372.47M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -33K | -192K | -2.71M | -142K | -21K | -76K | -77K |
Acquisitions Net | 0 | 9K | 2.7M | 118K | 0 | 0 | 0 |
Cash generated by investing activities | 16.34M | 53.36M | 130.61M | -281.69M | -21K | -76K | -77K |
Financing activities | |||||||
Common Stock Issued | 71.85M | 177K | 729K | 214.94M | 129.49M | 0 | 100K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -50K |
Cash used in financing activities | 71.93M | 177K | 729K | 214.94M | 127.75M | 52.31M | 9.97M |
Net Change In Cash | 21.56M | -31.53M | 31.19M | -118.89M | 103.06M | 43.78M | 7.54M |
Cash at end of period | 57.04M | 35.48M | 67.02M | 35.82M | 154.72M | 51.66M | 7.87M |
| Data source | Data source | Data source | Data source | Data source |